Skip to main content
. 2021 Aug 28;14:4967–4976. doi: 10.2147/IJGM.S321253

Figure 1.

Figure 1

Cumulative rates of virologic relapse, clinical relapse, HBeAg reversion, and HBsAg loss after discontinuation of NA therapy. (A) Clinical relapse, virological relapse, and HBeAg reversion were respectively observed in 44, 75, and 15 patients within 5 years of follow-up, with the cumulative incidence of 43.2%, 79.3%, and 13.2%. (B) Twelve patients cleared HBsAg, resulting in a cumulative incidence of 13.9% at year 5.